{"id":"W2080156752","doi":"10.1111/j.1525-1438.2005.00483.x","title":"A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer","year":2005,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":false,"ca_institutions":"Spinal Cord Injury BC","funders":"University of Pittsburgh","keywords":"Medicine; Concomitant; Ovarian cancer; Internal medicine; Adjuvant; Chemotherapy; Adverse effect; Monoclonal antibody; Immune system; Antibody; Oncology; Immunotherapy; Phases of clinical research; Cancer; Gastroenterology; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00185293,0.001593317,0.002723287,0.0007126117,0.0006615313,0.0009400899,0.001180497,0.001753269,0.002893769],"category_scores_gemma":[0.0008051171,0.0007241163,0.00163472,0.0004370277,0.001297258,0.0009672439,0.000402548,0.00358396,0.0008337303],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009750438,"about_ca_system_score_gemma":0.002002643,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002879884,"about_ca_topic_score_gemma":0.004240991,"domain_scores_codex":[0.9993914,0.0002323304,0.00002160939,0.0001012326,0.00005235889,0.0002011554],"domain_scores_gemma":[0.9994374,0.000092601,0.00007150677,0.00007808933,0.00003932159,0.0002810692],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5236521,0.248142,0.003291989,0.000633974,0.001076813,0.0005445656,0.0006140452,0.003096697,0.1517425,0.0005360196,0.003031755,0.06363765],"study_design_scores_gemma":[0.2164202,0.7685922,0.003957424,0.00001065455,0.0003307029,0.0001747296,0.00005748726,0.0007600856,0.007983086,0.0001230679,0.001570417,0.00001999005],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.993874,0.0006237932,0.0008609032,0.0002755442,0.0001394282,0.002777081,0.0005422278,0.00009018309,0.0008169221],"genre_scores_gemma":[0.9891102,0.0008298635,0.002074288,0.0005615829,0.0001865245,0.003342416,0.001224734,0.00004962177,0.002620673],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002893769,"threshold_uncertainty_score":0.009799361,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07371906642979087,"score_gpt":0.4565962377889497,"score_spread":0.3828771713591588,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}